INI-4001

Asset

Activates TLR7 and TLR8 to stimulate cytokine production and antitumor immune responses.

Stage
Phase 1
Modality
Small molecule
Target
TLR7
1
Indication
1
Trial
1
Developer

Named in the news on Nov 6, 2026. prnewswire.com

Indications

1

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials1
  • Evidence for its targets2
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets